Dipharma Francis S.R.L.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
1
Ending by 2030
Mar 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 14, 2027The maintenance fee for Synthesis of a glycosyltransferase inhibitor (US 9,079,856) comes due Jan 14, 2027. Unpaid by Jul 14, 2027, it lapses early.
- 1 fee due Feb 6, 2027The maintenance fee for Process for the preparation of crystalline dexlansoprazole (US 10,370,359) comes due Feb 6, 2027. Unpaid by Aug 6, 2027, it lapses early.
- 2 fees due Sep 24, 2027
- 1 fee due Nov 10, 2027The maintenance fee for Process for the purification of 2-phenyl-2-methyl-propanoic acid derivatives (US 9,334,223) comes due Nov 10, 2027. Unpaid by May 10, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,198,459 | Method for the preparation of rufinamide In force · From the USPTO record | In force | From the USPTO record | |
| US 8,314,241 | Process for the preparation of crystalline dexlansoprazole In force · From the USPTO record | In force | From the USPTO record | |
| US 8,455,678 | Process for the preparation of fesoterodine with low impurities content In force · From the USPTO record | In force | From the USPTO record | |
| US 8,809,553 | Process for the preparation of pteridine derivatives In force · From the USPTO record | In force | From the USPTO record | |
| US 8,530,691 | Process for the preparation of fesoterodine In force · From the USPTO record | In force | From the USPTO record | |
| US 8,772,340 | Process for the preparation of fesoterodine or a salt thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,884,016 | Apixaban preparation process In force · From the USPTO record | In force | From the USPTO record | |
| US 9,079,856 | Synthesis of a glycosyltransferase inhibitor In force · From the USPTO record | In force | From the USPTO record | |
| US 9,334,223 | Process for the purification of 2-phenyl-2-methyl-propanoic acid derivatives In force · From the USPTO record | In force | From the USPTO record | |
| US 9,751,828 | Antimuscarinic compound having a low content of impurities In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 17: 1 patent in force now held by others · 23 lapsed for an unpaid fee · 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 abandoned · 35 no status recorded